Ravi K Amaravadi, MD

faculty photo
Associate Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine

Contact information
Division of Hematology Oncology
8 BRB - Room 852
Philadelphia, PA 19104
Office: 215-769-5159
Education:
BA (Biochemistry )
Columbia University , 1996.
MD (Medicine)
Johns Hopkins University , 2000.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Autophagy, Mechanisms of Cell Death, Developmental Therapeutics

Description of Clinical Expertise

Phase I and Phase II Clinical Trials
Melanoma

Selected Publications

Mohiuddin JJ, Chu B, Facciabene A, Poirier K, Wang X, Doucette A, Zheng C, Xu W, Anstadt EJ, Amaravadi RK, Karakousis GC, Mitchell TC, Huang AC, Shabason JE, Lin A, Swisher-McClure S, Maity A, Schuchter LM, Lukens JN : Association of antibiotic exposure with survival and toxicity in patients with melanoma receiving immunotherapy. J. National Cancer Institute doi: 10.1093/jnci/djaa057, April 2020

Kwak T , Wang F, Deng H, Condamine T, Kumar V, Perego M, Kossenkov A, Montaner LJ, Xu X, Xu W, Zheng C, Schuchter LM , Amaravadi RK, Mitchell TC, Karakousis GC, Mulligan C, Nam B, Masters G, Hockstein N, Bennett J, Nefedova Y, Gabrilovich DI : Distinct Populations of Immune-Suppressive Macrophages Differentiate from Monocytic Myeloid-Derived Suppressor Cells in Cancer Cell Reports 33(13): doi: 10.1016/j.celrep.2020.108571, December 2020.

Haas NB, LaRiviere MJ, Buckingham TH, Cherkas Y, Calara-Nielsen K, Foulk B,Patel J,Gross S, Smirnov D, Vaughn DJ,Amaravadi R,Wellen KE,Savitch SL, Majmundar KJ, Black TA, Yee SS,He M,Min EJ, Long Q,Jones JO,Pal SK, Carpenter EL. : Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamide. Prostate Cancer and Prostatic Disease doi: 10.1038/s41391-020-00295, Oct 2020.

Xu C,Wang Lu, Fozouni P, Evjen G, Chandra V, Jiang J, Lu C, Nicastri M, Bretz C, Winkler JD, Amaravadi R, Garcia BA, Adams PD, Ott M, Tong W, Johansen T, Dou Z, Berger SL : SIRT1 is downregulated by autophagy in senescence and ageing. Nature Cell Biology 10: 1170-1179, Oct 2020.

Abella BS, Jolkovsky EL, Biney BT, Uspal JE,Hyman MC, Frank I, Hensley SE, Gill S, Vogl DT, Maillard I, Babushok DV, Huang AC, Nasta SD, Walsh JC, Wiletyo EP, Gimotty PA, Milone MC, Amaravadi RK and the Prevention and Treatment of COVID-19 With Hydroxychloroquine (PATCH) Investigators : Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial JAMA Internal Medicine Sept 2020 Notes: doi:10.1001/jamainternmed.2020.6319.

Sharma G, Ojha R, Noguera-Ortega E, Rebecca VW, Attanasio J, Liu S, Piao S, Lee J, Nicastri MC, Harper SL, Ronghe A, Jain V, Winkler JW, Speicher D, Mastio J, Gimotty PA, Xu X, Wherry EJ, Gabrilovich DI, Amaravadi RK.: PPT1 inhibition enhances the antitumor activity of anti-PD-1 antibody in melanoma JCI Insight 5(17): e133225, Sept 2020.

Zeh HJ, Bahary N, Boone BA, Singhi AD, Miller-Ocuin JL, Normolle DP, Zureikat AH, Hogg ME, Bartlett DL, Lee KK, Tsung A, Marsh JW, Murthy P, Tang D, Seiser N, Amaravadi RK, Espina V, Liotta L, Lotze MT : A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients Clinical Cancer Research 26(13): 3126, July 2020.

Beltra JC, Manne S, Abdel-Hakeem MS, Kurachi M, Giles JR, Chen Z, Casella V , Ngiow SF, Khan O, Huang YJ, Yan P, Nzingha K, Xu W, Amaravadi RK, Xu X, Karakousis GC, Mitchell TC, Schuchter LM, Huang AC, Wherry EJ : Developmental Relationships of Four Exhausted CD8 + T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms. Immunity 52(5): 825, May 2020.

Noman MZ, Parpal S, Van Moer K, Xiao M, Yu Y, Viklund J, De Milito A, Hasmim M,Andersson M, Amaravadi RK, Martinsson J,Berchem G, Janji B : Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti-PD-1/PD-L1 immunotherapy Science Advances 6(18): eaax7881, April 2020.

Marie R Webster, Mitchell E Fane, Gretchen M Alicea, Subhasree Basu, Andrew V Kossenkov, Gloria E Marino, Stephen M Douglass, Amanpreet Kaur, Brett L Ecker, Keerthana Gnanapradeepan, Abibatou Ndoye, Curtis Kugel, Alexander Valiga, Jessica Palmer, Qin Liu, Xiaowei Xu, Jessicamarie Morris, Xiangfan Yin, Hong Wu, Wei Xu, Cathy Zheng, Giorgos C Karakousis, Ravi K Amaravadi, Tara C Mitchell, Filipe V Almeida, Min Xiao, Vito W Rebecca, Ying-Jie Wang, Lynn M Schuchter, Meenhard Herlyn, Maureen E Murphy, Ashani T Weeraratna. : Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma. Molecular Cell 77(3): 681, Feb 6 2020.

back to top
Last updated: 02/17/2021
The Trustees of the University of Pennsylvania